# Pemetrexed and S-1 in Combination With Bevacizumab in Refractory Colorectal Cancer

> **NCT03843853** · PHASE2 · WITHDRAWN · sponsor: **The First Affiliated Hospital with Nanjing Medical University**

## Conditions studied

- Colorectal Neoplasms

## Interventions

- **DRUG:** Pemetrexed
- **DRUG:** S-1
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT03843853
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-05-01
- **Primary completion:** 2021-11-01
- **Final completion:** 2022-05-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** cooperation terminated
- **Last updated:** 2022-07-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03843853

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03843853, "Pemetrexed and S-1 in Combination With Bevacizumab in Refractory Colorectal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03843853. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*